GlassScriptPhysician profile
Roberto Feliz
NPI 1851376446
$6,920.95
in general payments reported to CMS, 2019-2025
30 companies · $220 in 2025
The $220 reported for 2025 was more than what 82% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,797 · 2020: $1,672 · 2021: $108 · 2022: $1,621 · 2023: $608 · 2024: $895 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,222.67 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,197.78 | 2022 | |
| Medtronic USA, INC. | $1,178.62 | 2019-2020 | |
| Boston Scientific Corporation | $1,048.80 | 2019-2024 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Painteq LLC | $736.64 | 2021-2024 | Painteq |
| Hydrocision, INC. | $500.00 | 2023 | Tenjet |
| Electronic Waveform Lab, INC. | $479.13 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $348.77 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.09 | 2019-2025 | Relistor |
| Zyla Life Sciences, INC. | $123.27 | 2019 | |
| Si-Bone, INC. | $111.18 | 2019 | |
| Medtronic, INC. | $97.40 | 2021-2025 | Inceptiv |
| Pfizer INC. | $94.02 | 2019-2024 | |
| Henry Schein, INC. | $83.11 | 2019 | |
| Abbvie INC. | $76.61 | 2021-2024 | |
| Bioventus LLC | $72.78 | 2024-2025 | Durolane, Supartz Fx Sodium Hyaluronate |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $62.48 | 2025 | |
| Biodelivery Sciences International, INC. | $58.00 | 2019 | |
| Tersera Therapeutics LLC | $56.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.16 | 2019 | |
| Amgen INC. | $41.50 | 2019 | |
| Lilly USA, LLC | $32.21 | 2019 | |
| Halozyme INC | $31.73 | 2023 | |
| Spr Therapeutics, INC | $30.41 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $27.62 | 2019-2020 | |
| Redhill Biopharma INC. | $24.71 | 2020 | |
| Biotronik Nro, INC. | $23.60 | 2025 | Prospera |
| Antares Pharma, INC. | $23.09 | 2022 | |
| Abbott Laboratories | $20.96 | 2020 | |
| Protega Pharmaceutials INC | $17.34 | 2025 | Roxybond |
| Galderma Laboratories, L.P. | $13.92 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Feliz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.